Intra-Arterial Liver-Directed Therapies for Neuroendocrine Hepatic Metastases

 

 Buy Article Permissions and Reprints

Abstract

Hepatic metastases, which are frequently seen in patients with neuroendocrine tumors (NETs), have a major adverse impact on the patient's quality of life and survival. Surgery is the treatment of choice for hepatic metastases but is possible in only a small percentage of patients. Systemic chemotherapy yields disappointing results. Somatostatin analogs are effective in controlling symptoms in many of these patients; however, the disease can become refractory to treatment. Transcatheter intra-arterial liver-directed therapies, such as hepatic artery embolization, chemoembolization, and radioembolization are frequently used in patients with NETs metastatic to the liver, especially in patients with refractory, unresectable, or recurrent disease. These treatments are effective in palliating the hormonal symptoms as well as achieving objective tumor responses. This review focuses on the technique, safety, and clinical efficacy of hepatic artery embolization, chemoembolization, and radioembolization in patients with metastatic NETs.

• References

• 1 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97 (4) 934-959
  CrossrefPubMedGoogle Scholar
• 2 Neary PC, Redmond PH, Houghton T, Watson GR, Bouchier-Hayes D. Carcinoid disease: review of the literature. Dis Colon Rectum 1997; 40 (3) 349-362
  CrossrefPubMedGoogle Scholar
• 3 Chamberlain RS, Canes D, Brown KT , et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000; 190 (4) 432-445
  CrossrefPubMedGoogle Scholar
• 4 Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79 (4) 813-829
  CrossrefPubMedGoogle Scholar
• 5 Modlin IM, Latich I, Kidd M, Zikusoka M, Eick G. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006; 4 (5) 526-547
  CrossrefPubMedGoogle Scholar
• 6 Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28: 317-336
  PubMedGoogle Scholar
• 7 O'Toole D, Hentic O, Corcos O, Ruszniewski P. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80 (Suppl. 01) 79-84
  CrossrefPubMedGoogle Scholar
• 8 Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass Jr HO. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984; 2 (11) 1255-1259
  PubMedGoogle Scholar
• 9 Brown DB, Gould JE, Gervais DA , et al; Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20 (7, Suppl) S425-S434
  CrossrefPubMedGoogle Scholar
• 10 Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006; 17 (8) 1235-1249; quiz 1250
  CrossrefPubMedGoogle Scholar
• 11 Liu DM, Kennedy A, Turner D , et al. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol 2009; 32 (2) 200-215
  CrossrefPubMedGoogle Scholar
• 12 Gupta S, Johnson MM, Murthy R , et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (8) 1590-1602
  CrossrefPubMedGoogle Scholar
• 13 Gupta S, Yao JC, Ahrar K , et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9 (4) 261-267
  CrossrefPubMedGoogle Scholar
• 14 Chamberlain RS, Canes D, Brown KT , et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000; 190 (4) 432-445
  CrossrefPubMedGoogle Scholar
• 15 Kamat PP, Gupta S, Ensor JE , et al. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol 2008; 31 (2) 299-307
  CrossrefPubMedGoogle Scholar
• 16 Steward MJ, Warbey VS, Malhotra A, Caplin ME, Buscombe JR, Yu D. Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics 2008; 28 (4) 1131-1145
  CrossrefPubMedGoogle Scholar
• 17 Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12 (8) 965-968
  CrossrefPubMedGoogle Scholar
• 18 Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002; 13 (11) 1163-1166
  CrossrefPubMedGoogle Scholar
• 19 Patel S, Tuite CM, Mondschein JI, Soulen MC. Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention. J Vasc Interv Radiol 2006; 17 (12) 1931-1934
  CrossrefPubMedGoogle Scholar
• 20 Khan W, Sullivan KL, McCann JW , et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol 2011; 197 (2) W343-W345
  CrossrefPubMedGoogle Scholar
• 21 Carrasco CH, Chuang VP, Wallace S. Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 1983; 149 (1) 79-83
  PubMedGoogle Scholar
• 22 Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986; 147 (1) 149-154
  CrossrefPubMedGoogle Scholar
• 23 Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 2003; 68 (2–3) 94-101
  CrossrefPubMedGoogle Scholar
• 24 Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988; 108 (3) 340-344
  CrossrefPubMedGoogle Scholar
• 25 Hanssen LE, Schrumpf E, Jacobsen MB , et al. Extended experience with recombinant alpha-2b interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report. Acta Oncol 1991; 30 (4) 523-527
  CrossrefPubMedGoogle Scholar
• 26 Bloomston M, Al-Saif O, Klemanski D , et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 2007; 11 (3) 264-271
  CrossrefPubMedGoogle Scholar
• 27 Brown KT, Koh BY, Brody LA , et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999; 10 (4) 397-403
  PubMedGoogle Scholar
• 28 Diamandidou E, Ajani JA, Yang DJ , et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 1998; 170 (2) 339-344
  CrossrefPubMedGoogle Scholar
• 29 Dominguez S, Denys A, Madeira I , et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 2000; 12 (2) 151-157
  CrossrefPubMedGoogle Scholar
• 30 Drougas JG, Anthony LB, Blair TK , et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175 (5) 408-412
  CrossrefPubMedGoogle Scholar
• 31 Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83 (11) 2293-2301
  CrossrefPubMedGoogle Scholar
• 32 Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 1992; 163 (5) 479-483
  CrossrefPubMedGoogle Scholar
• 33 Ho AS, Picus J, Darcy MD , et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188 (5) 1201-1207
  CrossrefPubMedGoogle Scholar
• 34 Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180 (5) 1379-1384
  CrossrefPubMedGoogle Scholar
• 35 Mavligit GM, Pollock RE, Evans HL, Wallace S. Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver. Cancer 1993; 72 (2) 375-380
  CrossrefPubMedGoogle Scholar
• 36 Moertel CG, Johnson CM, McKusick MA , et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994; 120 (4) 302-309
  CrossrefPubMedGoogle Scholar
• 37 Osborne DA, Zervos EE, Strosberg J , et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13 (4) 572-581
  CrossrefPubMedGoogle Scholar
• 38 Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116 (6) 1111-1116; discussion 1116–1117
  PubMedGoogle Scholar
• 39 Roche A, Girish BV, de Baère T , et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13 (1) 136-140
  PubMedGoogle Scholar
• 40 Ruszniewski P, Rougier P, Roche A , et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71 (8) 2624-2630
  CrossrefPubMedGoogle Scholar
• 41 Ruutiainen AT, Soulen MC, Tuite CM , et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18 (7) 847-855
  CrossrefPubMedGoogle Scholar
• 42 Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Contr 2006; 13 (1) 72-78
  PubMedGoogle Scholar
• 43 Therasse E, Breittmayer F, Roche A , et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993; 189 (2) 541-547
  PubMedGoogle Scholar
• 44 Varker KA, Martin EW, Klemanski D, Palmer B, Shah MH, Bloomston M. Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE. J Gastrointest Surg 2007; 11 (12) 1680-1685
  CrossrefPubMedGoogle Scholar
• 45 Wängberg B, Westberg G, Tylén U , et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996; 20 (7) 892-899; discussion 899
  CrossrefPubMedGoogle Scholar
• 46 Yao KA, Talamonti MS, Nemcek A , et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130 (4) 677-682; discussion 682–685
  CrossrefPubMedGoogle Scholar
• 47 Kim YH, Ajani JA, Carrasco CH , et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999; 17 (7) 474-478
  CrossrefPubMedGoogle Scholar
• 48 de Baere T, Deschamps F, Teriitheau C , et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008; 19 (6) 855-861
  CrossrefPubMedGoogle Scholar
• 49 Gaur SK, Friese JL, Sadow CA , et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011; 34 (3) 566-572
  CrossrefPubMedGoogle Scholar
• 50 Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011; 28 (Suppl. 01) S286-S290
  CrossrefPubMedGoogle Scholar
• 51 Murthy R, Nunez R, Szklaruk J , et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005; 25 (Suppl. 01) S41-S55
  CrossrefPubMedGoogle Scholar
• 52 Murthy R, Kamat P, Nunez R , et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 2008; 19 (1) 145-151
  CrossrefPubMedGoogle Scholar
• 53 Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (8) 1251-1278
  CrossrefPubMedGoogle Scholar
• 54 Mahvash A, Zaer N, Shaw C, Chasen B, Avritscher R, Murthy R. Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals. J Vasc Interv Radiol 2012; 23 (2) 277-280
  CrossrefPubMedGoogle Scholar
• 55 Kennedy AS, Dezarn WA, McNeillie P , et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31 (3) 271-279
  CrossrefPubMedGoogle Scholar
• 56 McStay MK, Maudgil D, Williams M , et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237 (2) 718-726
  CrossrefPubMedGoogle Scholar
• 57 King J, Quinn R, Glenn DM , et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113 (5) 921-929
  CrossrefPubMedGoogle Scholar
• 58 Rhee TK, Lewandowski RJ, Liu DM , et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247 (6) 1029-1035
  CrossrefPubMedGoogle Scholar
• 59 Kalinowski M, Dressler M, König A , et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009; 79 (3) 137-142
  CrossrefPubMedGoogle Scholar
• 60 Memon K, Lewandowski RJ, Mulcahy MF , et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83 (3) 887-894
  CrossrefPubMedGoogle Scholar
• 61 Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 2010; 251 (5) 910-916
  CrossrefPubMedGoogle Scholar
• 62 Kennedy AS, McNeillie P, Dezarn WA , et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74 (5) 1494-1500
  CrossrefPubMedGoogle Scholar
• 63 Krenning EP, Kwekkeboom DJ, Bakker WH , et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20 (8) 716-731
  PubMedGoogle Scholar
• 64 Krenning EP, Teunissen JJ, Valkema R, deHerder WW, deJong M, Kwekkeboom DJ. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. J Endocrinol Invest 2005; 28 (11) , Suppl International 146-150
  PubMedGoogle Scholar
• 65 McStay MK, Maudgil D, Williams M , et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237 (2) 718-726
  CrossrefPubMedGoogle Scholar
• 66 Limouris GS, Chatziioannou A, Kontogeorgakos D , et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2008; 35 (10) 1827-1837
  CrossrefPubMedGoogle Scholar
• 67 Takeuchi I, Ishida H, Suzuki T, Nakada H, Tada M, Idezuki Y. A case of liver metastases of rectal carcinoid successfully treated with hepatic arterial infusion of methotrexate and 5-fluorouracil [in Japanese]. Gan To Kagaku Ryoho 1999; 26 (12) 1929-1932
  PubMedGoogle Scholar
• 68 Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008; 144 (6) 885-893; discussion 893–894
  CrossrefPubMedGoogle Scholar